Dùng Zostavax hủng ngừa giảm nguy cơ bệnh con giời

FDA Licenses New Vaccine to Reduce Older Americans’ Risk of Shingles The Food and Drug Administration (FDA) licensed Zostavax, on May 25, 2006, a new vaccine to reduce the risk of shingles (herpes zoster) for use in people 60 years of age and older. "This vaccine gives health care providers an important tool that can help prevent an illness that affects many older Americans and often results in significant chronic pain," said Jesse L. Goodman, MD, MPH, Director of FDAs Center for Biologics Evaluation and Research. Zostavax, a live virus vaccine, was shown to boost immunity against varicella-zoster virus....
Nội dung trích xuất từ tài liệu:
Dùng Zostavax hủng ngừa giảm nguy cơ bệnh con giời Dùng Zostavax hủng ngừa giảm nguy cơ bệnh con giời FDA Licenses New Vaccine to Reduce Older Americans’ Risk ofShingles The Food and Drug Administration (FDA) licensed Zostavax, on May25, 2006, a new vaccine to reduce the risk of shingles (herpes zoster) for usein people 60 years of age and older. This vaccine gives health care providers an important tool that canhelp prevent an illness that affects many older Americans and often resultsin significant chronic pain, said Jesse L. Goodman, MD, MPH, Director ofFDAs Center for Biologics Evaluation and Research. Zostavax, a live virus vaccine, was shown to boost immunity againstvaricella-zoster virus. This is thought to be the mechanism by which thevaccine protects against zoster and its complications. The vaccine is given asa single injection under the skin, preferably in the upper arm. Zostavax was studied in approximately 38,000 individuals throughoutthe United States who were 60 years of age and older. Of these 38,000people, half received Zostavax and half received a placebo. All studyparticipants were then followed for an average of three years to see if theydeveloped shingles and, if they did, how long the pain lasted. At the conclusion of the study, researchers found that, overall, in thoseages 60 and above the vaccine reduced the occurrence of shingles by about50%. For individuals ages 60-69 it reduced occurrence by 64%. In addition to preventing approximately half of the cases, the durationof pain following the onset of shingles was slightly reduced in people whodeveloped the disease–despite being vaccinated with Zostavax. As part of the development program, a smaller study was conducted tolook more closely at safety. In this smaller study, serious adverse events forall age groups were noted more frequently in those who received Zostavax(1.9%) than those who received placebo (1.3%). Although FDA hasconcluded that the available data do not establish that these events arerelated to the vaccine, the manufacturer will perform a Phase 4 (postmarket)study to provide additional safety information. Zostavax is manufactured by Merck & Co., Inc., of WhitehouseStation, New Jersey.